Example: bankruptcy
Cutaneous Solution Pl
Found 2 free book(s)
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euAfter dilution (see section 6.6) , the final concentration of the diluted solution should be between 3.2 and 16.8 mg/m L. *Atezolizumab is an Fc -engineered, humanised IgG1 anti -programmed death- ligand 1 (PD -L1)
European Medicines Agency
www.ema.europa.euEuropean Medicines Agency 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 71 29 E-mail: qrd@emea.europa.eu www.emea.europa.eu